These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16807644)

  • 1. Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade.
    Nazareth RA; Tomaz LS; Ortiz-Costa S; Atella GC; Ribeiro JM; Francischetti IM; Monteiro RQ
    Thromb Haemost; 2006 Jul; 96(1):7-13. PubMed ID: 16807644
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    De Paula VS; Silva FHS; Francischetti IMB; Monteiro RQ; Valente AP
    Biomol NMR Assign; 2017 Oct; 11(2):293-296. PubMed ID: 28856584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.
    Francischetti IM; Valenzuela JG; Andersen JF; Mather TN; Ribeiro JM
    Blood; 2002 May; 99(10):3602-12. PubMed ID: 11986214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite.
    Monteiro RQ; Rezaie AR; Bae JS; Calvo E; Andersen JF; Francischetti IM
    Protein Sci; 2008 Jan; 17(1):146-53. PubMed ID: 18042685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis.
    Francischetti IM; Mather TN; Ribeiro JM
    Thromb Haemost; 2004 May; 91(5):886-98. PubMed ID: 15116248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixolaris: a factor Xa heparin-binding exosite inhibitor.
    Monteiro RQ; Rezaie AR; Ribeiro JM; Francischetti IM
    Biochem J; 2005 May; 387(Pt 3):871-7. PubMed ID: 15617517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant expression of Ixolaris, a Kunitz-type inhibitor from the tick salivary gland, for NMR studies.
    De Paula VS; Silva FHS; Francischetti IMB; Monteiro RQ; Valente AP
    Protein Expr Purif; 2017 Nov; 139():49-56. PubMed ID: 28734839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition.
    De Paula VS; Sgourakis NG; Francischetti IMB; Almeida FCL; Monteiro RQ; Valente AP
    Blood; 2019 Aug; 134(8):699-708. PubMed ID: 31133602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting exosites on blood coagulation proteases.
    Monteiro RQ
    An Acad Bras Cienc; 2005 Jun; 77(2):275-80. PubMed ID: 15895163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.
    Collin N; Assumpção TC; Mizurini DM; Gilmore DC; Dutra-Oliveira A; Kotsyfakis M; Sá-Nunes A; Teixeira C; Ribeiro JM; Monteiro RQ; Valenzuela JG; Francischetti IM
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2185-98. PubMed ID: 22796577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of
    Barboza T; Gomes T; da Costa Medeiros P; Ramos IP; Francischetti I; Monteiro RQ; Gutfilen B; de Souza SAL
    Clin Exp Metastasis; 2020 Aug; 37(4):489-497. PubMed ID: 32394234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis.
    Mizurini DM; Francischetti IM; Andersen JF; Monteiro RQ
    Thromb Haemost; 2010 Dec; 104(6):1116-23. PubMed ID: 20838739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
    Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
    Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
    Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
    Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
    Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
    Hollenbach S; Sinha U; Lin PH; Needham K; Frey L; Hancock T; Wong A; Wolf D
    Thromb Haemost; 1994 Mar; 71(3):357-62. PubMed ID: 8029801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
    Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
    Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
    J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.